US 12,168,003 B2
Selective inhibition of T follicular helper cells for treatment of autoimmune disorders
Preeyam S. Patel, New York, NY (US); and Robert J. Schneider, New York, NY (US)
Assigned to NEW YORK UNIVERSITY, New York, NY (US)
Filed by NEW YORK UNIVERSITY, New York, NY (US)
Filed on Feb. 6, 2023, as Appl. No. 18/165,113.
Application 18/165,113 is a continuation of application No. 17/110,023, filed on Dec. 2, 2020, granted, now 11,602,524.
Claims priority of provisional application 62/942,503, filed on Dec. 2, 2019.
Prior Publication US 2023/0233535 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/426 (2006.01); C12Q 1/68 (2018.01)
CPC A61K 31/426 (2013.01) [C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01)] 15 Claims
 
1. A method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject, said method comprising:
administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject, wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis (MS), rheumatoid arthritis, asthma, allergies and food allergies, anaphylactic responses, Jorgen syndrome, autoimmune encephalitis (EAE), lupus nephritis, Type I diabetes, juvenile dermatomyositis, autoimmune myasthenia gravis, autoimmune thyroid disease, atherosclerosis, and graft versus host disease.